Grants and Contracts Details
A Phase 2 a Multi-Center Study of 18FDG-PET, Satey, and Tolerability of AZD0530 in Mild Alzheimer's Disease. The project will test the potential benefit of AZ0530 for Alzheimer's disease modification. This is a phase 2a multi-center, randomized, double-blind, placebo, controlled study evaluating 18FDG--PET, safety, and tolerability of AZDO0530 in 152 patients with mild AD.
|Effective start/end date||8/1/14 → 5/31/15|
- University of California San Diego Health: $30,450.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.